FASLG and cancer: As expected, unlike the effects observed in cancer cells, the viability of HUVECs, HBE cells, and induced pluripotent stem cell (iPS)-derived cardiomyocytes was minimally affected by the combination of fasudil and sFasL (84.0%, 75.9%, and 89.6%, respectively, compared to the control) (Fig. 3b; Supplementary Videos 2, 3).